2014—2018年我国中药药物经济学研究文献质量评价

Literature of Chinese herbal medicine economics research from 2014 to 2018:a quality assessment

目的:通过对中药药物经济学研究文献进行质量评价,了解国内中药药物经济学评价存在的问题和优势。方法:检索2014-2018年的中药药物经济学评价文献,采用目前大家比较认可、综合《中国药物经济学评价指南》、Drummond MF和Chiou CF等的药物经济学文献评价标准的12项评价指标进行质量评价。结果:国内中药药物经济学研究存在着研究视角不明确、经费支持少、研究年限短、成本计算局限、结局可比性差等问题,同时也有研究结合实际、研究设计标准、注重敏感性分析、结局指标恰当等优势。结论:为了促进中药药物经济学评价的规范化发展,政府应制定法律明确需使用药物经济学评价,同时加大人才培养和基金支持力度,有条件还应建立全面的数据分析体系。

Objective:To understand the problems and advantages in the evaluation of traditional Chinese medicine(TCM)pharmacoeconomics through the quality evaluation of the research literature.Methods:Literature about the evaluation of TCM pharmacoeconomics from 2014 to2018 were searched,and the quality evaluation was conducted by using the 12 evaluation index systems that have been widely recognized,which combined with the evaluation standards of pharmacoeconomics in China and literatures writed by Drummond MF and Chiou CF,etc.Results:There are some problems in the study of TCM pharmacoeconomics,including unclear research perspective,little financial support,short research period,limited cost calculation,and poor comparability of outcomes.In addition,it also has the advantages of combining research with practice,standardizing research design,focusing on sensitivity analysis,and making a appropriate outcome indicators.Conclusion:In order to promote the standardized development of TCM pharmacoeconomics evaluation,the government should formulate laws to specify the use of pharmacoeconomic evaluation,strengthen personnel training and fund support,and establish a comprehensive data analysis system when conditions permit.